About Bioanalytical Systems, Inc.BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company") today announced its Board of Directors has appointed Dr. Peter T. Kissinger, founder and former Executive Chairman and CEO of BASi, as a scientific advisor to the Company. "The Board and the employees at BASi are very pleased to have Pete back at the Company," said Larry Boulet, Board Chairman of BASi. "Pete's experience and background in the study of modern bioanalytical instrumentation and in vivo methodology for drug metabolism and the neurosciences are well known. In Pete's new role, he will work closely with our staff across all products and service offerings to capitalize on the inherent strengths of our people and processes. He will help guide the Company's continuing program to expand our market reach and position BASi to deliver profitable growth over the long-term. We look forward to the many exciting developments resulting from Pete's new role." "My decision to take on this role at this important time for BASi is fueled by my conviction that the people, products and services at BASi are capable of growing and expanding the Company's activities both internally and in partnership with other industry leaders," said Dr. Kissinger. Dr. Kissinger brings over 40 years of experience and recognition in outstanding contributions to, and success with, commercializing research discoveries. He has published more than 250 scientific papers and is a fellow of the American Association of Pharmaceutical Scientists and the American Association for the Advancement of Science. He is a regular columnist for the trade publication Drug Discovery News and serves on the boards of Chembio Diagnostic Systems Inc., a NASDAQ-listed company; the Indiana Health Industry Forum; and Tymora, a recent Purdue-based startup company. In 2007 Peter Kissinger and Candice Kissinger founded Phlebotics Inc., a development-stage medical device company focused on diagnostic information for intensive-care medicine. In 2005 he became chairman and interim CEO of Prosolia, which markets new mass spectrometry innovations for life science applications. Peter Kissinger was a founder of the first Purdue University new business incubator, INventure, in the late 1980s. Dr. Kissinger has a bachelor's degree in chemistry from Union College in Schenectady, N.Y., and a doctorate in analytical chemistry from the University of North Carolina.